Publications

Detailed Information

Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma

DC Field Value Language
dc.contributor.authorKwon, Jeanny-
dc.contributor.authorKim, Il Han-
dc.contributor.authorKim, Byoung Hyuck-
dc.contributor.authorKim, Tae Min-
dc.contributor.authorHeo, Dae Seog-
dc.date.accessioned2024-05-14T01:36:23Z-
dc.date.available2024-05-14T01:36:23Z-
dc.date.created2018-09-07-
dc.date.created2018-09-07-
dc.date.issued2015-05-
dc.identifier.citationInternational Journal of Radiation Oncology Biology Physics, Vol.92 No.1, pp.91-98-
dc.identifier.issn0360-3016-
dc.identifier.urihttps://hdl.handle.net/10371/201712-
dc.description.abstractPurpose: The purpose of this study was to evaluate the role of involved-lesion radiation therapy (ILRT) after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy in limited stage diffuse large B-cell lymphoma (DLBCL) by comparing outcomes of R-CHOP therapy alone with R-CHOP followed by ILRT. Methods and Materials: We identified 198 patients treated with R-CHOP (median, 6 cycles) for pathologically confirmed DLBCL of limited stage from July 2004 to December 2012. Clinical characteristics of these patients were 33% with stage I and 66.7% with stage II; 79.8% were in the low or low-intermediate risk group; 13.6% had B symptoms; 29.8% had bulky tumors (>= 7 cm); and 75.3% underwent >= 6 cycles of R-CHOP therapy. RT was given to 43 patients (21.7%) using ILRT technique, which included the prechemotherapy tumor volume with a median margin of 2 cm (median RT dose: 36 Gy). Results: After a median follow-up of 40 months, 3-year progression-free survival (PFS) and overall survival (OS) were 85.8% and 88.9%, respectively. Multivariate analysis showed >= 6 cycles of R-CHOP (PFS, P = .004; OS, P = .004) and ILRT (PFS, P = .021; OS, P = .014) were favorable prognosticators of PFS and OS. A bulky tumor (P = .027) and response to R-CHOP (P = .012) were also found to be independent factors of OS. In subgroup analysis, the effect of ILRT was prominent in patients with a bulky tumor (PFS, P = .014; OS, P = .030) or an elevated level of serum lactate dehydrogenase (LDH; PFS, P = .004; OS, P = .012). Conclusions: Our results suggest that ILRT after R-CHOP therapy improves PFS and OS in patients with limited stage DLBCL, especially in those with bulky disease or an elevated serum LDH level. (C) 2015 Published by Elsevier Inc.-
dc.language영어-
dc.publisherElsevier BV-
dc.titleAdditional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma-
dc.typeArticle-
dc.identifier.doi10.1016/j.ijrobp.2014.12.042-
dc.citation.journaltitleInternational Journal of Radiation Oncology Biology Physics-
dc.identifier.wosid000353988200014-
dc.identifier.scopusid2-s2.0-84927577854-
dc.citation.endpage98-
dc.citation.number1-
dc.citation.startpage91-
dc.citation.volume92-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorKim, Il Han-
dc.contributor.affiliatedAuthorKim, Byoung Hyuck-
dc.contributor.affiliatedAuthorHeo, Dae Seog-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusNON-HODGKINS-LYMPHOMA-
dc.subject.keywordPlusPOSTCHEMOTHERAPY FDG-PET-
dc.subject.keywordPlusPLUS RADIOTHERAPY-
dc.subject.keywordPlusRESPONSE CRITERIA-
dc.subject.keywordPlusONCOLOGY-GROUP-
dc.subject.keywordPlusTRIAL-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

Kim, Byoung hyuck Image

Kim, Byoung hyuck김병혁
(기금)조교수
  • College of Medicine
  • Department of Medicine
Research Area 소화기암, 육종, 폐암

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share